Christopher B. Ehrlich - Aug 25, 2021 Form 4 Insider Report for eFFECTOR Therapeutics, Inc. (EFTR)

Role
Director
Signature
/s/ Michael Byrnes, Attorney-in-Fact for Chris Ehrlich
Stock symbol
EFTR
Transactions as of
Aug 25, 2021
Transactions value $
$0
Form type
4
Date filed
8/27/2021, 06:53 PM
Next filing
Oct 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EFTR Common Stock Conversion of derivative security $0 +142K $0.00 142K Aug 25, 2021 By Locust Walk Partners LLC F1
transaction EFTR Common Stock Conversion of derivative security $0 +1.03K $0.00 1.03K Aug 25, 2021 By Locust Walk Partners LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EFTR Class B Common Stock Disposed to Issuer $0 -133K -48.3% $0.00 142K Aug 25, 2021 Common Stock 133K By Locust Walk Partners LLC F1, F3, F4, F5
transaction EFTR Class B Common Stock Conversion of derivative security -142K -100% 0 Aug 25, 2021 Common Stock 142K By Locust Walk Partners LLC F1, F3
transaction EFTR Class B Common Stock Disposed to Issuer $0 -966 -48.3% $0.00 1.03K Aug 25, 2021 Common Stock 966 By Locust Walk Partners LLC( F2, F3, F4, F5
transaction EFTR Class B Common Stock Conversion of derivative security -1.03K -100% 0 Aug 25, 2021 Common Stock 1.03K By Locust Walk Partners LLC F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares held directly by the Sponsor, of which Locust Walk Partners LLC ("LWP") is a member. LWP has allocated these shares to the reporting person.
F2 Represents shares held directly by the Sponsor, of which LWP is a member. LWP has allocated these shares to the reporting person's spouse.
F3 On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). In connection with and upon consummation of the Merger, each of the Issuer's outstanding shares of Class B Common Stock automatically converted into one share of Class A Common Stock and such shares of Class A Common Stock were automatically reclassified in shares of common stock.
F4 Pursuant to an agreement by and between the Issuer and Locust Walk Sponsor, LLC (the "Sponsor"), concurrent with the consummation of the Merger, these shares of Class B Common Stock were forfeited to the Issuer immediately prior to the Merger.
F5 As a former principal of the manager of the Sponsor, the reporting person previously reported all securities held by the Sponsor. As of the date hereof, the reporting person is no longer a principal of the entity with control over the securities held by the Sponsor, accordingly, this report only includes securities to the extent of the reporting person's and his spouse's pecuniary interest therein.